Moneycontrol PRO
Upcoming Webinar:Moneycontrol Pro in association with Quants League Sep'21 Edition brings to you to 5-Days Live Algorithmic Options Trading Virtual Conference. Register Now!
you are here: HomeNewsBusiness

Buy Jubilant Pharmova; target of Rs 850: ICICI Direct

ICICI Direct is bullish on Jubilant Pharmova has recommended buy rating on the stock with a target price of Rs 850 in its research report dated July 24, 2021.

July 28, 2021 / 09:43 AM IST


  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Jubilant Pharmova

Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses. Formulations - 24% of FY21 revenues, Radiopharma and allergy therapy – 38%, and CDMO & API – 33% of sales It has six USFDA approved manufacturing facilities in India, US and Canada


Despite regulatory concerns, we remain positive and retain our BUY rating on the stock  We value Jubilant at Rs 850 i.e. 10x P/E on FY23E EPS

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jul 28, 2021 09:43 am

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark